Several prior studies have highlighted abnormal activation of PI3K/AKT/mTOR and JAK/STAT pathways in childhood Ph-like ALL models [18] and have demonstrated improved anti-leukemia efficacy upon combining type I JAK1/2 inhibitor ruxolitinib and PI3K/mTOR inhibitors [11, 18, 22]. This evidence concerns the gene SOAT1 and acute lymphoblastic leukemia.